Federated Hermes, Inc. Surface Oncology, Inc. Transaction History

Federated Hermes, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	SELL	$0.61 - $1.03 $82 - $140	-136 Reduced 4.9%	2,638 $1,000
Q4 2022 Feb 13, 2023	BUY	$0.62 - $1.21 $1,005 - $1,962	1,622 Added 140.8%	2,774 $2,000
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $1,209 - $2,419	1,152 New	1,152 $1,000
Q1 2022 May 13, 2022	SELL	$2.65 - $5.08 $7 - $15	-3 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $14 - $23	3 New	3 $1,000
Q1 2021 May 13, 2021	SELL	$7.25 - $13.82 $3,233 - $6,163	-446 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$6.87 - $10.48 $3,064 - $4,674	446 New	446 $4,000
Q4 2019 Feb 14, 2020	SELL	$1.17 - $2.33 $858 - $1,710	-734 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$1.4 - $2.84 $1,159 - $2,351	-828 Reduced 53.01%	734 $1,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $4.89 $4,295 - $7,638	1,562 New	1,562 $4,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.